AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEJM publishes Phase III study data for Salix' XIFAXAN in NonC IBS.
(From Pharma)
M2PHARMA-January 6, 2011-NEJM publishes Phase III study data for Salix' XIFAXAN in Non-C IBS (C)2011 M2 COMMUNICATIONS http://www.m2.com
6 January 2011 - US Salix Pharmaceuticals Ltd (NASDAQ: SLXP) said on Wednesday that the New England Journal of Medicine (NEJM) has published results from TARGET 1 and TARGET 2, its two pivotal Phase III efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.
The studies showed XIFAXAN 550 mg tablets demonstrated a statistically significant improvement for the adequate relief of global IBS symptoms, IBS-related …
-
- Significant symptom relief reported in cilansetron Phase III clinical trial...
-
News wire article from: Asia Africa Intelligence Wire
May 19, 2004
700+ words
-
- Cilansetron improves health related quality of life in multinational Phase...
-
News wire article from: Asia Africa Intelligence Wire
November 1, 2004
700+ words
-
- Alizyme announces successful preliminary results of its Phase IIb clinical...
-
News wire article from: Asia Africa Intelligence Wire
September 24, 2003
700+ words
-
- Forest to discontinue development in US of dexloxiglumide for irritable bowel...
-
News wire article from: Asia Africa Intelligence Wire
October 1, 2003
700+ words
-
- Takeda, Yamanouchi, Eisai aiming at IBS medication.
-
News wire article from: Asia Africa Intelligence Wire
January 13, 2005
700+ words
